KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial.

Sady A Alpizar, Jose Accini, Duane C Anderson, Basem Eysa, Isaí Medina-Piñón, Norio Ohmagari, Mykola M Ostrovskyy, Angela Aggrey-Amable, Karen Beck, Dana Byrne, Staci Grayson, Peggy M T Hwang, Julia D Lonchar, Julie Strizki, Yayun Xu, Amanda Paschke, Carisa S De Anda, Pamela S Sears, MOVe-AHEAD study group

J Infect 87(5) 392-402

PMID37690669
PMCID-
DOI10.1016/j.jinf.2023.08.016
发表日期2023-09-10
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVES: To evaluate the efficacy and safety of molnupiravir for intra-household post-exposure prophylaxis (PEP) of COVID-19. METHODS: MOVe-AHEAD was a randomized, controlled, double-blind, phase 3 trial comparing molnupiravir (800 mg twice daily for 5 days) with placebo. Eligible participants were adult, unvaccinated, asymptomatic household contacts of patients with laboratory-confirmed COVID-19. The primary efficacy endpoint was the incidence of COVID-19 through day 14 in modified intention-to-treat (MITT) participants (those who received ≥1 dose of study intervention) without detectable SARS-CoV-2 at baseline, termed the MITT-VN population. Superiority of molnupiravir was prespecified as a stratified one-sided p-value of <0.0249 for the treatment difference in this endpoint. RESULTS: The MITT population comprised 763 participants randomized to molnupiravir and 764 to placebo; 83.6% had anti-SARS-CoV-2 antibodies at baseline. In the MITT-VN population, COVID-19 rates through day 14 were 6.5% with molnupiravir and 8.5% with placebo (one-sided p-value: 0.0848). In the molnupiravir arm, 25/35 of confirmed COVID-19 events (71.4%) occurred after completion of treatment (versus 17/49 [34.7%] for placebo). Adverse event rates were low and similar between molnupiravir and placebo. CONCLUSIONS: Molnupiravir was well-tolerated but did not meet the prespecified superiority criterion, possibly influenced in part by the high pre-existing immunity in the trial population.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。